Market Research Logo

The Chinese Market for Cancer Intervention

The Chinese Market for Cancer Intervention

The Chinese cancer intervention market reached nearly $41.1 billion in 2016. This market should reach $46.7 billion in 2017 and $89.3 billion by 2022, at a compound annual growth rate (CAGR) of 13.8% through 2022.

Report Includes
An overview of the Chinese market for cancer intervention.
Analyses of global market trends, with data from 2016, estimates for 2017, and projections of compound annual growth rates (CAGRs) through 2022.
Coverage of current procedures as well as those expected to be realized over the next five years.
Analysis of the market's dynamics, specifically growth drivers, restraints, and opportunities
Profiles of major players in the industry.

Report Scope
The scope of the report includes cancer intervention applications, industries, markets, and companies in China. The markets for cancer intervention are given for the years 2016, 2017 and 2022. 
The Chinese cancer intervention market includes two major segments: cancer treatment and cancer diagnosis and detection. Each major segment will be further divided and discussed by technology, drug type, end user, etc.

In this report, China is referred to as Mainland China. It does not include Hong Kong, Macao and Taiwan. Mainland China has a total of 31 province-level regions, including 22 provinces, four province-level municipalities (cities), and five province-level autonomous regions. Important geographic markets will be discussed, including Beijing, Shanghai and others.


Chapter 1: Introduction
Study Goals and Objectives
Reasons for Doing This Study
Scope of Report
Information Sources
Methodology
Geographic Breakdown
Analyst's Credentials
Related BCC Research Reports
Chapter 2: Summary and Highlights
Largest Segments in the Chinese Cancer Intervention Market
Fastest Growing Segments in the Chinese Cancer Intervention Market
Chapter 3: Market and Technology Background
Market Background
Number of Cancer Cases in China
Geographical Distribution
Medical System
Drug Distribution System in China
Sales Channels
Key Trends in the Chinese Cancer Intervention Market
Technology Background
Key Technology Trends in the Chinese Cancer Intervention Market
Chapter 4: Market Breakdown by Technology Type
Antitumor Drugs
Immunopotentiators
Immunosuppressors
Adjuvant Drugs
Cancer Surgery
Radiotherapy
Diagnosis and Detection
Chapter 5: Market Breakdown by Product
Drugs used for Cancer Treatment in China
Antitumor Drugs and Immunomodulators
Adjuvant Drugs
Cancer Surgery
Radiotherapy
Diagnosis and Detection
Chapter 6: Market Breakdown by End Use
Chinese Lung Cancer Intervention Market
Chinese Lung Cancer Drug Market
Chinese Lung Cancer Surgery Market
Chinese Lung Cancer Radiotherapy Market
Chinese Lung Cancer Diagnosis and Detection Market
Chinese Gastric Cancer Intervention Market
Chinese Gastric Cancer Drug Market
Chinese Gastric Cancer Surgery Market
Chinese Gastric Cancer Radiotherapy Market
Chinese Gastric Cancer Diagnosis and Detection Market
Chinese Liver Cancer Intervention Market
Chinese Liver Cancer Drug Market
Chinese Liver Cancer Surgery Market
Chinese Liver Cancer Radiotherapy Market
Chinese Liver Cancer Diagnosis and Detection Market
Chinese Esophageal Cancer Intervention Market
Chinese Esophageal Cancer Drug Market
Chinese Colorectal Cancer Intervention Market
Chinese Colorectal Cancer Drug Market
Chinese Breast Cancer Intervention Market
Chinese Breast Cancer Drug Market
Market of Other Cancer Types in China
Thyroid Cancer Drug Permission in China
Leukemia Drug Permission in China
Pancreatic Cancer Drug Permission in China
Lymphoma Drug Permission in China
Ovarian, Cervical and Fallopian Tube Drug Permission in China
Melanoma Drug Permission in China
Chapter 7: Market Breakdown by Region
East China Cancer Intervention Market
Middle China Cancer Intervention Market
North China Cancer Intervention Market
Southwest China Cancer Intervention Market
Northwest China Cancer Intervention Market
Northeast China Cancer Intervention Market
South China Cancer Intervention Market
Chapter 8: Analysis of Market Opportunities
Reference Listed Drugs
Generic Drugs
Surgery Materials
Radiotherapy Equipment
DNA Sequencing
Traditional Chinese Drugs
Chapter 9: Company Profiles
Appendix: Glossary
About BCC Research
About BCC Research
BCC Membership
BCC Custom Research
List of Tables
Summary Table: Chinese Market for Cancer Intervention, by Service Type, Through 2022 ($ Millions)
Table 1 Cancer Cases and Shares in China, by Indication, in 2015 (Thousand, %)
Table 2 Cancer Cases and Rates in China, by Indication, in 2015 (Thousand, per 100,000 People)
Table 3 Number of Hospitals in China, by Type, 2014 and 2015
Table 4 Number of City and County Hospitals in China, by Grade, 2014 and 2015
Table 5 Number of City and County Hospitals in China, by Ownership, 2014 and 2015
Table 6 Numbers of Town and Village Hospitals in China, by Type, 2014 and 2015
Table 7 Key Market Trends for the Cancer Intervention Market in China
Table 8 Key Technology Trends for Cancer Intervention in China
Table 9 Chinese Market for Cancer Intervention, by Major Segments, Through 2022 ($ Millions)
Table 10 Chinese Antitumor Drug Market, by Technology Type, Through 2022 ($ Millions)
Table 11 Chinese Immunopotentiator Market, by Technology Type, Through 2022 ($ Millions)
Table 12 Chinese Immunosuppressor Market, by Technology Type, Through 2022 ($ Millions)
Table 13 Chinese Adjuvant Drug Market, by Technology Type, Through 2022 ($ Millions)
Table 14 Chinese Cancer Surgery Market, by Surgery Purpose, Through 2022 ($ Millions)
Table 15 Chinese Radiotherapy Market, by Technology Type, Through 2022 ($ Millions)
Table 16 Chinese Cancer Diagnosis and Detection Market, by Technology Type, Through 2022 ($ Millions)
Table 17 Chinese Market for Cancer Intervention, by Major Type, Through 2022 ($ Millions)
Table 18 Chinese Market for Cancer Treatment, by Major Purpose, Through 2022 ($ Millions)
Table 19 Drugs for Cancer Treatment in China, by Product Type, Through 2022 ($ Millions)
Table 20 Chinese Antitumor Drug and Immunomodulators Market, by Product Type, Through 2022 ($ Millions)
Table 21 Chinese Antitumor Drug Market, by Product, Through 2022 ($ Millions)
Table 22 Chinese Paclitaxel Market, by Product, Through 2022 ($ Millions)
Table 23 Chinese Paclitaxel Market Share, by Product, in 2016 ($ Millions/%)
Table 24 Chinese Pemetrexed Disodium Market, by Producer, Through 2022 ($ Millions)
Table 25 Chinese Pemetrexed Disodium Market Share, by Producer, in 2016 ($ Millions/%)
Table 26 Chinese Docetaxel Market, by Producer, Through 2022 ($ Millions)
Table 27 Chinese Docetaxel Market Share, by Producer, in 2016 ($ Millions/%)
Table 28 Chinese Tegafur/Gimeracil/Oteracil Market, by Producer, Through 2022 ($ Millions)
Table 29 Chinese Tegafur/Gimeracil/Oteracil Market Share, by Producer, in 2016 ($ Millions/%)
Table 30 Chinese Oxaliplatin Market, by Producer, Through 2022 ($ Millions)
Table 31 Chinese Oxaliplatin Market, by Producer, in 2016 ($ Millions/%)
Table 32 Chinese Imatinib Market, by Producer, Through 2022 ($ Millions)
Table 33 Chinese Imatinib Market Share, by Producer, in 2016 ($ Millions/%)
Table 34 Chinese Capecitabine Market, by Producer, Through 2022 ($ Millions)
Table 35 Chinese Capecitabine Market Share, by Producer, in 2016 ($ Millions/%)
Table 36 Chinese Rituximab Market, by Producer, Through 2022 ($ Millions)
Table 37 Chinese Trastuzumab Market, by Producer, Through 2022 ($ Millions)
Table 38 Chinese Immunomodulator Market, by Product, Through 2022 ($ Millions)
Table 39 Chinese Thymopentin Market, by Producer, Through 2022 ($ Millions)
Table 40 Chinese Thymopentin Market Share, by Producer, 2016 ($ Millions/%)
Table 41 Chinese Tacrolimus Market, by Producer, Through 2022 ($ Millions)
Table 42 Chinese Tacrolimus Market Share, by Producer, in 2016 ($ Millions/%)
Table 43 Chinese Antitumor Drug and Immunomodulator Market, by Product, Through 2022 ($ Millions)
Table 44 Chinese Chemical and Biological Antitumor Drug and Immunomodulator Market, by Product, Through 2022 ($ Millions)
Table 45 Traditional Chinese Antitumor Drug and Immunomodulator Market, by Product, Through 2022 ($ Millions)
Table 46 Chinese Antitumor Drug and Immunomodulator Market, by Sales Channel, Through 2022 ($ Millions)
Table 47 Chinese Hospital Antitumor Drug and Immunomodulator Market, by Hospital Type, Through 2022 ($ Millions)
Table 48 Chinese Chemical & Biological Antitumor Drug and Immunomodulator Market, by Hospital Type, Through 2022 ($ Millions)
Table 49 Traditional Chinese Antitumor Drug and Immunomodulator Market, by Hospital Type, Through 2022 ($ Millions)
Table 50 Chemical and Biological Drug Market in Hospitals in China, by Drug Type and Hospital Type, 2016 ($ Millions)
Table 51 Traditional Chinese Drug Market in Hospitals in China, by Drug Type and Hospital Type, in 2016 ($ Millions)
Table 52 Chinese Retail Drug Market, by Drug Type, Through 2022 ($ Millions)
Table 53 Chinese Adjuvant Drug Market, by Product Type, Through 2022 ($ Millions)
Table 54 Chinese Antiemetic Drug Market, by Product Type, Through 2022 ($ Millions)
Table 55 Chinese Cancer Surgery Market, by Product and Service Type, Through 2022 ($ Millions)
Table 56 Chinese Radiotherapy Market, by Service Type, Through 2022 ($ Millions)
Table 57 Chinese Radiotherapy Equipment Market, by Service Type, Through 2022 ($ Millions)
Table 58 Chinese Cancer Diagnosis and Detection Market, by Service Type, Through 2022 ($ Millions) 80
Table 59 Chinese Cancer DNA Sequencing Diagnosis and Detection Market, by Indication, Through 2022 ($ Millions)
Table 60 Chinese Cancer DNA Sequencing Diagnosis and Detection Market, by Test Purpose, Through 2022 ($ Millions)
Table 61 Chinese Cancer DNA Sequencing Diagnosis and Detection Market, by Test Complexity, Through 2022 ($ Millions)
Table 62 Chinese Cancer Intervention Market, by Cancer Type, Through 2022 ($ Millions)
Table 63 Chinese Lung Cancer Intervention Market, by Service Type, Through 2022 ($ Millions)
Table 64 Chinese Lung Cancer Intervention Market Comparison, by Service Type, 2016 (%)
Table 65 Chinese Lung Cancer Drug Market, by Product, Through 2022 ($ Millions)
Table 66 Tinibs for Lung Cancer Intervention in China, by Drug, 2016 ($ Millions/%)
Table 67 Lung Cancer Targeting Drug Permission in China, 2016
Table 68 Chinese Gastric Cancer Intervention Market, by Service Type, Through 2022 ($ Millions)
Table 69 Chinese Gastric Cancer Intervention Market Comparison, by Service Type, 2016 (%)
Table 70 Chinese Liver Cancer Intervention Market, by Service Type, Through 2022 ($ Millions)
Table 71 Chinese Liver Cancer Intervention Market Comparison, by Service Type, 2016 (%)
Table 72 Chinese Esophageal Cancer Intervention Market, by Service Type, Through 2022 ($ Millions) 95
Table 73 Chinese Esophageal Cancer Intervention Market Comparison, by Service Type, 2016 (%)
Table 74 Chinese Colorectal Cancer Intervention Market, by Service Type, Through 2022 ($ Millions) .. 97
Table 75 Chinese Colorectal Cancer Intervention Market Comparison, by Service Type, 2016 ($ Millions)
Table 76 Colorectal Cancer Targeting Drug Permission in China, 2016
Table 77 Chinese Breast Cancer Intervention Market, by Service Type, Through 2022 ($ Millions)
Table 78 Chinese Breast Cancer Intervention Market Comparison, by Service Type, 2016 (%)
Table 79 Breast Cancer Targeting Drug Permission in China, 2016
Table 80 Chinese Cancer Intervention Market for Other Cancers, by Service Type, Through 2022 ($ Millions)
Table 81 Thyroid Cancer Targeting Drug Permission in China, 2016
Table 82 Leukemia Cancer Targeting Drug Permission in China, 2016
Table 83 Pancreatic Cancer Targeting Drug Permission in China, 2016
Table 84 Lymphoma Targeting Drug Permission in China, 2016
Table 85 Ovarian, Cervical and Fallopian Tube Cancer Targeting Drug Permission in China, 2016
Table 86 Melanoma Targeting Drug Permission in China, 2016
Table 87 Chinese Cancer Intervention Market, by Region, Through 2022 ($ Millions)
Table 88 East China Cancer Intervention Market, by Province, Through 2022 ($ Millions)
Table 89 East China Cancer Intervention Market per Capita, by Province, in 2016 ($ Millions)
Table 90 Middle China Cancer Intervention Market, by Province, Through 2022 ($ Millions)
Table 91 Middle China Cancer Intervention Market per Capita, by Province, in 2016 ($ Millions)
Table 92 North China Cancer Intervention Market, by Province, Through 2022 ($ Millions)
Table 93 North China Cancer Intervention Market per Capita, by Province, in 2016 ($ Millions)
Table 94 Southwest China Cancer Intervention Market, by Province, Through 2022 ($ Millions)
Table 95 Southwest China Cancer Intervention Market per Capita, by Province, in 2016 ($ Millions)
Table 96 Northwest China Cancer Intervention Market, by Province, Through 2022 ($ Millions)
Table 97 Northwest China Cancer Intervention Market per Capita, by Province, in 2016 ($ Millions)
Table 98 Northeast China Cancer Intervention Market, by Province, Through 2022 ($ Millions)
Table 99 Northeast China Cancer Intervention Market per Capita, by Province, in 2016 ($ Millions)
Table 100 South China Cancer Intervention Market, by Province, Through 2022 ($ Millions)
Table 101 South China Cancer Intervention Market per Capita, by Province, in 2016 ($ Millions)
Table 102 Lung Cancer Targeting Drug Permission in China, 2016
Table 103 Astellas Sales in China, Through 2022 ($ Millions)
Table 104 AstraZeneca’s Sales in China, Through 2022 ($ Millions)
Table 105 Bayer Drug Sales in China, Through 2022 ($ Millions)
Table 106 Bristol-Myers Squibb Cancer Drug Sales in China, Through 2022 ($ Millions)
Table 107 Chiatai Tianqing Cancer Drug Sales in China, Through 2022 ($ Millions)
Table 108 Fsens Cancer Drug Sales in China, Through 2022 ($ Millions)
Table 109 Yibai Cancer Drug Sales in China, Through 2022 ($ Millions)
Table 110 Hahsoh Cancer Drug Sales in China, Through 2022 ($ Millions)
Table 111 Hengrui Cancer Drug Sales in China, Through 2022 ($ Millions)
Table 112 Johnson & Johnson Drug Sales in China, Through 2022 ($ Millions)
Table 113 Lunan Drug Sales in China, Through 2022 ($ Millions)
Table 114 Luye Drug Sales in China, Through 2022 ($ Millions)
Table 115 MSD Drug Sales in China, Through 2022 ($ Millions)
Table 116 Novartis Drug Sales in China, Through 2022 ($ Millions)
Table 117 Pfizer Drug Sales in China, Through 2022 ($ Millions)
Table 118 Qilu Drug Sales in China, Through 2022 ($ Millions)
Table 119 Roche Drug Sales in China, Through 2022 ($ Millions)
Table 120 Sanofi Drug Sales in China, Through 2022 ($ Millions)
Table 121 Kanglaite Drug Sales in China, Through 2022 ($ Millions)
Table 122 Glossary/Abbreviations in this Report
List of Figures
Summary Figure: Chinese Market for Cancer Intervention, by Service Type, 2016-2022 ($ Millions)
Figure 1 Drug Supply Chain in China
Figure 2 Chinese Market for Cancer Intervention, by Major Segments, 2016-2022 ($ Millions)
Figure 3 Chinese Market for Cancer Intervention, by Major Type, 2016-2022 ($ Millions)
Figure 4 Chinese Paclitaxel Market Share, by Product, 2016 (%)
Figure 5 Chinese Pemetrexed Disodium Market Share, by Producer, 2016 (%)
Figure 6 Chinese Docetaxel Market Share, by Producer, 2016 (%)
Figure 7 Chinese Tegafur/Gimeracil/Oteracil Market Share, by Producer, 2016 (%)
Figure 8 Chinese Oxaliplatin Market, by Producer, 2016 (%)
Figure 9 Chinese Imatinib Market Share, by Producer, 2016 (%)
Figure 10 Chinese Capecitabine Market Share, by Producer, 2016 (%)
Figure 11 Chinese Thymopentin Market Share, by Producer, 2016 (%)
Figure 12 Chinese Tacrolimus Market Share, by Producer, 2016 (%)
Figure 13 Chinese Cancer Intervention Market, by Region, 2016-2022 ($ Millions)

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report